ObesityPhase 3NCT07654374
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
A Phase 3 study testing aleniglipron in people with Obesity and Overweight, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics at 74 sites in United States.
Trial summary
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment. Read more about this study
- Who is it for?
- Ages 18 to 79 yearsHealthy volunteers can take part
- Conditions the study is for
- Obesity, Overweight, Chronic Weight Management
- What is being tested?
- aleniglipron
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,100 participants
- Where
- 74 sitesUnited States
- Study dates
- 17 Jul 2026to Nov 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 79 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Signed Informed Consent
- Have a BMI ≥27.0 kg/m2 at Screening
- Have a diagnosis of T2DM according to the WHO classification or other locally applicable standards, with HbA1c ≥6.5% (≥53 mmol/mol) to ≤10% (86 mmol/mol) at Screening
Who cannot join
- Have type 1 diabetes, history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM.
- Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 180 days prior to Screening.
- Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
- Self-reported change in body weight >5 kg (11 pounds) within 3 months before Screening.
- Have prior or planned surgical or non-surgical treatment for obesity.
Trial locations and contacts
74 sites in 1 country. Contact the study team or a site near you to ask about taking part.
74 sites in 1 country
United States74 sites, 74 recruiting
- Not yet recruiting
ACCOMPLISH-2 Research Site
Albany, New York, 12206
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Albany, New York, 12208
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Atlanta, Georgia, 30329
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Austin, Texas, 78704
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Birmingham, Alabama, 35242
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Brooklyn, New York, 11220
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Burke, Virginia, 22015
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Chandler, Arizona, 85225
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Charlotte, North Carolina, 28210
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Chesterfield, Missouri, 63005
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
City of Saint Peters, Missouri, 63303
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Clearwater, Florida, 33756
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Columbus, Georgia, 31904
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Columbus, Ohio, 43213
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Des Moines, Iowa, 50314
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Durham, North Carolina, 27710
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Escondido, California, 92025
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Farmers Branch, Texas, 75234
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Fayetteville, North Carolina, 28304
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Fort Myers, Florida, 33912
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Fountain Valley, California, 92708
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Greer, South Carolina, 29651
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Gulfport, Mississippi, 39503
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Hazelwood, Missouri, 63042
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Houston, Texas, 77040
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Houston, Texas, 77054
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Iowa City, Iowa, 52242
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Jacksonville, Florida, 32216
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
La Jolla, California, 92123
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Lake Forest, California, 92630
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Las Vegas, Nevada, 89128
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Lawrenceville, Georgia, 30046
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Leesburg, Florida, 34748
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Little Rock, Arkansas, 72211
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Manassas, Virginia, 20110
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Mankato, Minnesota, 56001
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Meridian, Idaho, 83646
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Methuen, Massachusetts, 01844
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Miami, Florida, 33136
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Minneapolis, Minnesota, 55423
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Missoula, Montana, 59804
Medical Director GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Moore, Oklahoma, 73160
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Morehead City, North Carolina, 23730
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Nashville, Tennessee, 37203
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Ocala, Florida, 34470
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Ocoee, Florida, 34761
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Omaha, Nebraska, 68105
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Pembroke Pines, Florida, 33027
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Philadelphia, Pennsylvania, 19152
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Phoenix, Arizona, 85028
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Portland, Oregon, 97202
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Renton, Washington, 98057
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Ridgeland, Mississippi, 39157
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Rolling Hills Estates, California, 90274
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Salt Lake City, Utah, 84107
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
San Antonio, Texas, 78229
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
San Antonio, Texas, 78230
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
San Diego, California, 92108
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Silver Spring, Maryland, 20901
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Springfield, Missouri, 65807
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
St Louis, Missouri, 63141
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Suffolk, Virginia, 23435
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Sun City West, Arizona, 85375
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
The Bronx, New York, 10455
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Tucson, Arizona, 85741
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Tulsa, Oklahoma, 74133
Medical Director, GSBRClinicalTrials@structuretx.com
- Not yet recruiting
ACCOMPLISH-2 Research Site
Tustin, California, 92780
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Union City, Georgia, 30291
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Waterbury, Connecticut, 06708
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Wichita, Kansas, 67218
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Winston-Salem, North Carolina, 27104
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Woodstock, Georgia, 30189
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Wylie, Texas, 75098
Medical Director, GSBRClinicalTrials@structuretx.com
- Recruiting
ACCOMPLISH-2 Research Site
Yukon, Oklahoma, 73099
Medical Director, GSBRClinicalTrials@structuretx.com
About this study
Official title: A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.
- Being tested
- aleniglipron, Placebo
- Keywords
- obesity, overweight, GSBR-1290, aleniglipron, chronic weight management, obese, type 2diabetes mellitus, small molecule, GLP-1, Structure Therapeutics
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
aleniglipronDrug
Drug: aleniglipron administered orally
aleniglipronDrug
Drug: aleniglipron administered orally
aleniglipronDrug
Drug: aleniglipron administered orally
PlaceboDrug
Drug: placebo administered orally
| Study group | Role | What they receive |
|---|---|---|
| aleniglipron Arm 1 | Experimental | Participants will receive aleniglipron administered orally. Receives: Drug: aleniglipron |
| aleniglipron Arm 2 | Experimental | Participants will receive aleniglipron administered orally. Receives: Drug: aleniglipron |
| aleniglipron Arm 3 | Experimental | Participants will receive aleniglipron administered orally. Receives: Drug: aleniglipron |
| Placebo Arm 4 | Placebo comparator | Participants will receive placebo administered orally. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent change in body weight from Baseline
Measured: Baseline and week 76
Secondary outcomes (9)
Change in body weight (absolute) from Baseline
Measured: Baseline and week 76
Percentage of participants who achieve ≥5% reduction in body weight
Measured: Baseline and week 76
Percentage of participants who achieve ≥10% reduction in body weight
Measured: Baseline and week 76
Percentage of participants who achieve ≥15% reduction in body weight
Measured: Baseline and week 76
Change in waist circumference from Baseline
Measured: Baseline and week 76
Change in HbA1c from Baseline
Measured: Baseline and week 76
Change in resting systolic blood pressure from Baseline
Measured: Baseline and week 76
Percent change in fasting triglycerides and non-HDL cholesterol from Baseline
Measured: Baseline and week 76
Percentage of participants achieving HbA1c target value of ≤6.5%
Measured: Baseline and week 76
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start17 Jul 2026
- Primary completionSep 2028 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 1,100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07654374
- Sponsor's protocol ID
- GSBR-1290-15
- Status last verified
- Jun 2026
- First submitted
- 12 Jun 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual patient data for variables necessary to address a specific research question in an approved data sharing request
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ClinicalTrials.gov ID
- NCT07654374
- Acronym / sponsor ID
- GSBR-1290-15
- Keywords
- obesity, overweight, GSBR-1290, aleniglipron, chronic weight management, obese, type 2diabetes mellitus, small molecule
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,100 participants (estimated)
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- 17 Jul 2026 (actual)
- Primary completion
- Sep 2028 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 17 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| aleniglipron Arm 1 | Experimental | Drug: aleniglipronParticipants will receive aleniglipron administered orally. |
| aleniglipron Arm 2 | Experimental | Drug: aleniglipronParticipants will receive aleniglipron administered orally. |
| aleniglipron Arm 3 | Experimental | Drug: aleniglipronParticipants will receive aleniglipron administered orally. |
| Placebo Arm 4 | Placebo comparator | Drug: PlaceboParticipants will receive placebo administered orally. |
Who may qualify
- Ages
- 18 to 79 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Signed Informed Consent
- Have a BMI ≥27.0 kg/m2 at Screening
- Have a diagnosis of T2DM according to the WHO classification or other locally applicable standards, with HbA1c ≥6.5% (≥53 mmol/mol) to ≤10% (86 mmol/mol) at Screening
Key exclusion criteria (5 listed)
- Have type 1 diabetes, history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM.
- Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 180 days prior to Screening.
- Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
- Self-reported change in body weight >5 kg (11 pounds) within 3 months before Screening.
- Have prior or planned surgical or non-surgical treatment for obesity.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| aleniglipronDrug: aleniglipron administered orally | Drug | aleniglipron Arm 1 |
| aleniglipronDrug: aleniglipron administered orally | Drug | aleniglipron Arm 2 |
| aleniglipronDrug: aleniglipron administered orally | Drug | aleniglipron Arm 3 |
| PlaceboDrug: placebo administered orally | Drug | Placebo Arm 4 |
Primary outcome
Percent change in body weight from Baseline
Time frame: Baseline and week 76
9 secondary outcomes
Change in body weight (absolute) from Baseline
Time frame: Baseline and week 76
Percentage of participants who achieve ≥5% reduction in body weight
Time frame: Baseline and week 76
Percentage of participants who achieve ≥10% reduction in body weight
Time frame: Baseline and week 76
Percentage of participants who achieve ≥15% reduction in body weight
Time frame: Baseline and week 76
Change in waist circumference from Baseline
Time frame: Baseline and week 76
Change in HbA1c from Baseline
Time frame: Baseline and week 76
Change in resting systolic blood pressure from Baseline
Time frame: Baseline and week 76
Percent change in fasting triglycerides and non-HDL cholesterol from Baseline
Time frame: Baseline and week 76
Percentage of participants achieving HbA1c target value of ≤6.5%
Time frame: Baseline and week 76
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: Yes. De-identified individual patient data for variables necessary to address a specific research question in an approved data sharing request
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
74 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing aleniglipron in people with Obesity and Overweight, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics at 74 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 74 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Medical Director (1-650-457-1959, GSBRClinicalTrials@structuretx.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent change in body weight from Baseline (time frame: Baseline and week 76). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.